Arena Pharmaceuticals
SAN DIEGO, CA · CIK 0001080709 · Biotech · Acquired
Ralinepag, an oral prostacyclin receptor agonist small molecule therapeutic
arenapharm.com →- Grants
- $106K
- 1 award
- Sector median: 1
- Raised
- $187M
- 2 Form D · Jun 2010
- 196 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 2 granted · 5 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓1999200120032005200720092011
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · 5HT2A Receptor Inverse Agonists As Novel Antipsychotics | $106,000 | |
| Private capital raised | Form D · SEC | $151,760,000 | |
| Private capital raised | Form D · SEC | $35,530,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2829 | NEPHROGEN INC. | — | — |
| 2830 | JUNIPERO THERAPEUTICS, INC. | — | — |
| 2831 | Inceptive Nucleics, Inc. | — | $100M |
| 2832 | Arena Pharmaceuticals | — | $187M |
| 2833 | Prelude Therapeutics | — | $97M |
| 2834 | Coriell Life Sciences, Inc. | — | $10M |
| 2835 | Tango Therapeutics | — | $95M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- K.A. AJIT-SIMHExecutive Officer
- DOMINIC BEHANDirector · Executive Officer
- DONALD BELCHERDirector
- SCOTT BICEDirector
- HARRY HIXSON, JR.Director
- ROBERT HOFFMANExecutive Officer
- J. LA FORCE, JR.Director
- JACK LIEFDirector · Executive Officer
- TINA NOVADirector
- PHILLIP SCHNEIDERDirector
- WILLIAM SHANAHAN, JR.Executive Officer
- STEVEN SPECTORExecutive Officer
- CHRISTINE WHITEDirector
- RANDALL WOODSDirector
Patents
- Methods Of Treating Conditions Related To The S1P1 Receptorgranted
- Crystalline L-arginine Salt Of (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3, 4-TETRAHYDROCYCLO-PENTA [B]INDOL-3-YL)ACETIC ACID(COMPOUND1) For Use In Sipi Receptor-associated Disordersgranted
- Modulators Of The BETA-3 Adrenergic Receptor Useful For The Treatment Or Prevention Of Heart Failureapplication
- Modulators Of The Prostacyclin (PGI2) Receptor Useful For The Treatment Of Disorders Related Theretoapplication
- Modulators Of The BETA-3 Adrenergic Receptor Useful For The Treatment Or Prevention Of Disorders Related Theretoapplication
- Modulators Of The Beta-3 Adrenergic Receptor Useful For The Treatment Or Prevention Of Renal Cystic Disease and Cardiorenal Syndromeapplication
- Administration of a Compound to Individuals with Hepatic Impairmentapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.